Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide - An overview

被引:387
作者
Ignarro, LJ
Napoli, C
Loscalzo, J
机构
[1] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Evans Dept Med, Boston, MA 02118 USA
[2] Univ Calif Los Angeles, Ctr Hlth Sci, Nitr Oxide Res Grp, Los Angeles, CA 90024 USA
[3] Univ Naples Federico II, Dept Med, Naples, Italy
[4] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
关键词
oxidant stress; cardiovascular pharmacology; endothelium; vascular type; nitric oxide;
D O I
10.1161/hh0102.102330
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nitric oxide (NO) mediates multiple physiological and pathophysiological processes in the cardiovascular system. Pharmacological compounds that release NO have been useful tools for evaluating the pivotal role of NO in cardiovascular physiology and therapeutics. These agents constitute two broad classes of compounds, those that release NO or one of its redox congeners spontaneously and those that require enzymatic metabolism to generate NO. In addition, several commonly used cardiovascular drugs exert their beneficial action, in part, by modulating the NO pathway. Here, we review these classes of agents, summarizing their fundamental chemistry and pharmacology, and provide an overview of their cardiovascular mechanisms of action.
引用
收藏
页码:21 / 28
页数:8
相关论文
共 107 条
[61]   Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin [J].
Momi, S ;
Emerson, M ;
Paul, W ;
Leone, M ;
Mezzasoma, AM ;
Del Soldato, P ;
Page, CP ;
Gresele, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 397 (01) :177-185
[62]   Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase - A new action for an old drug [J].
Munzel, T ;
Kurz, S ;
Rajagopalan, S ;
Thoenes, M ;
Berrington, WR ;
Thompson, JA ;
Freeman, BA ;
Harrison, DG .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (06) :1465-1470
[63]   Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-Mediated superoxide production, and vascular NO bioavailability [J].
Münzel, T ;
Li, H ;
Mollnau, H ;
Hink, U ;
Matheis, E ;
Hartmann, M ;
Oelze, M ;
Skatchkov, M ;
Warnholtz, A ;
Duncker, L ;
Meinertz, T ;
Förstermann, U .
CIRCULATION RESEARCH, 2000, 86 (01) :E7-E12
[64]   EVIDENCE FOR ENHANCED VASCULAR SUPEROXIDE ANION PRODUCTION IN NITRATE TOLERANCE - A NOVEL MECHANISM UNDERLYING TOLERANCE AND CROSS-TOLERANCE [J].
MUNZEL, T ;
SAYEGH, H ;
FREEMAN, BA ;
TARPEY, MM ;
HARRISON, DG .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (01) :187-194
[65]  
Murad F, 1998, RECENT PROG HORM RES, V53, P43
[66]   Nifedipine and nisoldipine modulate membrane potential of vascular endothelium via a myo-endothelial pathway [J].
Muraki, K ;
Watanabe, M ;
Imaizumi, Y .
LIFE SCIENCES, 2000, 67 (26) :3163-3170
[67]  
MURRELL W, 1879, LANCET, V1, P642
[68]  
Murrell W., 1879, LANCET, V1, P80
[69]  
MURRELL W, 1879, LANCET, V1, P224
[70]  
MURRELL W, 1879, LANCET, V1, P151